Get the Stockscreener App
5.34
5.82%
-0.33
Serina Therapeutics Inc stock is traded at $5.34, with a volume of 15,288.
It is down -5.82% in the last 24 hours and up +7.23% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$5.67
Open:
$5.75
24h Volume:
15,288
Relative Volume:
1.09
Market Cap:
$53.04M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+15.58%
1M Performance:
+7.23%
6M Performance:
-25.31%
1Y Performance:
+0.00%
1-Day Range:
$5.00
$5.75
1-Week Range:
$4.51
$5.82
52-Week Range:
$3.81
$10.28
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
5.34 | 53.04M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Serina Therapeutics Inc Stock (SER) Latest News
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Serina Cuts $11.2M Debt, Secures $10M Investment While Revenue Drops 98% - Stock Titan
Serina Therapeutics to Present Novel Data on Non-Immunogenic Lipid Nanoparticles at ACS Spring 2025 Meeting - Nasdaq
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting - GlobeNewswire
Revolutionary Drug Platform Eliminates Major Safety Risk in mRNA Vaccines and Gene Therapies - Stock Titan
Jones Trading Initiates Coverage of Serina Therapeutics (SER) with Buy Recommendation - Nasdaq
Serina Therapeutics initiated with a Buy at JonesResearch - TipRanks
Serina Therapeutics Appoints Dr. Venkatesan to Board - TipRanks
Serina Therapeutics Appoints Dr. Jay Venkatesan to Board of Directors - Nasdaq
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors - GlobeNewswire
Former Alpine Immune Sciences Founder Who Led $4.9B Exit Takes Board Seat at Serina - StockTitan
Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial - MSN
Serina secures additional $5 million for Parkinson's trial - MSN
Serina secures additional $5 million for Parkinson's trial By Investing.com - Investing.com Australia
Stocks to Watch: Palantir Technologies, Synaptics, J&J Snack Foods, Serina Therapeutics - MarketWatch
Serina Therapeutics's Shares Up Following $5M of Equity Financing - MarketWatch
Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash Position - Marketscreener.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Serina Therapeutics receives funding to advance SER-252 into clinical trial - TipRanks
Serina Therapeutics Secures $5 Million for SER-252 Trials - TipRanks
Serina Therapeutics Receives Second $5 Million Tranche to - GlobeNewswire
Parkinson's Breakthrough: Serina Therapeutics Lands Premium-Priced $5M Investment to Advance Novel Treatment - StockTitan
Serina Therapeutics Secures Additional $5 Million Financing to Advance SER-252 into Phase 1 Trial for Advanced Parkinson's Disease - Nasdaq
Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics - MarketWatch
Serina Therapeutics Shares Rise After Sale of UniverXome Subsidiary - MarketWatch
Serina Therapeutics Sells UniverXome Subsidiary - MarketWatch
Serina Therapeutics Announces Sale of UniverXome Subsidiary - GlobeNewswire
Serina Therapeutics Achieves Debt-Free Status After $11.2M UniverXome Sale, Sharpens Focus on Parkinson's Drug - StockTitan
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors - GlobeNewswire
Serina Therapeutics, Inc. Appoints Karen J. Wilson to its Board of Directors -January 14, 2025 at 05:25 pm EST - Marketscreener.com
Serina Therapeutics director Bailey Gregory buys shares worth $17,744 By Investing.com - Investing.com Australia
Serina Therapeutics director Bailey Gregory buys shares worth $17,744 - Investing.com
Serina Therapeutics expands equity incentive plan By Investing.com - Investing.com Australia
Serina Therapeutics expands equity incentive plan - Investing.com India
Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024 - BioSpace
Serina Therapeutics to Present at Tribe Public’s Webinar - GlobeNewswire
Serina Therapeutics to Unveil Breakthrough Parkinson's Treatment Strategy in Upcoming Webinar - StockTitan
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit - GlobeNewswire
Serina Therapeutics Unveils Breakthrough LNP Technology: Zero Immune Response in Key Testing - StockTitan
Serina raises $10M to develop SER-252 for advanced Parkinson’s - Parkinson's News Today
Serina Therapeutics Raises $10M in Financing - FinSMEs
Serina Therapeutics, Inc. announced that it expects to receive $10 million in funding - Marketscreener.com
Serina Therapeutics Stock Soars Pre-Market On $10M Equity Deal To Fund Parkinson’s Trials: Retail Sentiment Explodes - MSN
Serina Therapeutics Stock Soars Pre-Market On $10M Equity Deal To Fund Parkinson’s Trials: Retail Sentiment Ex - Asianet Newsable
Serina Therapeutics Shares Rise After $10 Million in Financing - MarketWatch
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket - Benzinga
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients - The Manila Times
Serina Therapeutics secures $10M financing - TipRanks
Serina Therapeutics Secures $10 Million Financing to - GlobeNewswire
Serina Therapeutics Secures $10M Financing for Parkinson's Drug Trial at 120% Premium - StockTitan
Serina Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Serina Therapeutics Inc Stock (SER) Financials Data
There is no financial data for Serina Therapeutics Inc (SER). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.89%
0.13%
Cap:
|
Volume (24h):